Agonists that enhanced binding of integrin-expressing cells to integrin receptors

Patent metadata

Field	Value
Publication number	US-10035784-B2
Application number	US-201514751452-A
Country	US
Kind code	B2
Filing date	Jun 26, 2015
Priority date	Nov 16, 2010
Publication date	Jul 31, 2018
Grant date	Jul 31, 2018

Abstract

A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

First claim

What is claimed is:

1. A chemical compound having the general formula (I)

wherein
R 1 is a substituted phenyl group, or a substituted or unsubstituted thienyl, furyl, pyridyl, thiazolyl, oxazolyl, or isoxazolyl group,
R 2 is aralkyl,
M 1 is CH 2 ,
M 2 is SO 2 or CO,
M 3 is absent or is CH 2 ,
M 4 is absent or is CH 2 ,
M 5 is CHR 12 ,
R 12 is selected from the group consisting of hydrogen, or alkyl,
M 6 is (CH 2 ) q , or NR 34 (CH 2 ) q , wherein q is an integer from 1 to 2,
R 3 is selected from the group consisting of CONR 13 R 14 , SO 2 NR 13 R 14 , NR 15 COR 16 , NR 15 CONR 13 R 14 , and NR 15 SO 2 R 16 ,
R 15 , when present, is independently selected from the group of hydrogen, and C 1 -C 6 alkyl,
R 16 , when present, is selected from the group consisting of C 1 -C 6 alkyl, aralkyl, and aryl,
R 13 , and R 14 , each of which when present, is independently selected from the group consisting of hydrogen, and aralkyl,
R 34 , when present, is selected from the group consisting of hydrogen, alkyl, and COR 35 ,
R 35 , when present, is alkyl, and
R 1 , R 2 , R 13 , R 14 , R 15 , R 16 , R 34 and R 35 , when present, may be either unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, azido, haloalkoxy, halo, haloalkyl, amino, alkylamino, and dialkylamino,
provided that when M 2 is CO, then M 6 is NR 34 (CH 2 ) q wherein q is 1 or 2.

2. A compound selected from the group consisting of N-{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}-N-(2-thienylmethyl)thiophene-2-sulfonamide; N-{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}-N-(2-thienylmethyl)thiophene-2-carboxamide; 2-{butyl[(2-thienylmethyl)carbamoyl]amino}-N,N-bis(2-thienylmethyl)ethanesulfonamide; 2-{[bis(2-thienylmethyl)carbamoyl](butyl)amino}-N,N-bis(2-thienylmethyl)ethanesulfonamide; N-{3-[bis(2-thienylmethyl)sulfamoyl]propyl}-N-(2-thienylmethyl)thiophene-2-sulfonamide; 2-[(methyl sulfonyl)(2-thienylmethyl)amino]-N,N-bis(2-thienylmethyl)ethanesulfonamide; 2-{[bis(2-thienylmethyl)carbamoyl]amino}-N,N-bis(2-thienylmethyl)ethanesulfonamide; N-{2-[bis(2-thienylmethyl)sulfamoyl]ethylthiophene-2-sulfonamide; N-{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}-2-(2-thienyl)acetamide; N-{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}thiophene-2-carboxamide; N,N-bis(2-thienylmethyl)-2-{[(2-thienylmethyl)carbamoyl]amino}ethanesulfonamide; 2-({2-[bis(2-thienylmethyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylmethyl)acetamide; 3-[{2-[bis(2-thienylmethyl)amino]-2-oxoethyl}(butyl)amino]-N,N-bis(2-thienylmethyl)propanamide; 2-[{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}(methyl)amino]-N,N-bis(2-thienylmethyl)acetamide; 2-[{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}(butyl)amino]-N,N-bis(2-thienylmethyl)acetamide; 3-({2-[bis(2-thienylmethyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylmethyl)propanamide; 3-({2-[bis(2-thienylmethyl)sulfamoyl]ethyl}amino)-N,N-bis(4-methoxybenzyl)propanamide; 3-({2-[bis(4-methoxybenzyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylmethyl)propanamide; 3-[{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}(methyl)amino]-N,N-bis(2-thienylmethyl)propanamide; 3-[{2-[bis(4-methoxybenzyl)sulfamoyl]ethyl}(methyl)amino]-N,N-bis(2-thienylmethyl)propanamide; (2 S)-2-({2-[bis(2-thienylmethyl)sulfamoyl]ethylamino)-N,N-bis(2-thienylmethyl)hexanamide; (2 S)-2-({2-[bis(4-methoxybenzyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylmethyl)hexanamide; 2-(acetyl{2-[bis(2-thienylmethyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylmethyl)acetamide; and 2-(acetyl{2-[bis(4-methoxybenzyl)sulfamoyl]ethyl}amino)-N,N-bis(2-thienylmethyl)acetamide.

3. A pharmaceutical composition comprising:
a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier.

Assignees

• Texas Heart Inst

Inventors

• Biediger Ronald J
• Savage Michael M

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K35/51

  Umbilical cord; Umbilical cord blood; Umbilical stem cells · CPC title

• C07C271/22

  to carbon atoms of hydrocarbon radicals substituted by carboxyl groups · CPC title

• C07D409/12

  linked by a chain containing hetero atoms as chain links · CPC title

• A61K35/12

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title